FBLG Stock News & Catalysts

FEATURED

FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents

Newly Granted Patent Covers Methods of Preparing Fibroblasts to Home to Tumors and Carry Oncolytic Viruses and Other Anti-Cancer AgentsHOUSTON, Nov. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG)

Summary

Nov 5, 2026, 8:30 AM ·PRNewswire

RECENT

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

FSdC Spheroids Preserved Disc Height Better Than Any Other Fibroblast-Based Approach Tested in a 12-Week Rabbit Model of Degenerative Disc DiseaseHOUSTON, Oct. 19, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG)

Oct 19, 2026, 8:30 AM ·PRNewswire

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged

Oct 14, 2026, 8:30 AM ·PRNewswire

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

New approach proposes an alternative to repeated injectionsHOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents

Oct 7, 2026, 8:30 AM ·PRNewswire

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc RegenerationHOUSTON, Sept. 29,

Sep 29, 2026, 8:30 AM ·PRNewswire

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on

Sep 17, 2026, 8:30 AM ·PRNewswire

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of WoundsHOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc.

Sep 3, 2026, 8:30 AM ·PRNewswire

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated FibroblastsHOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"

Sep 1, 2026, 8:30 AM ·PRNewswire

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on

Aug 27, 2026, 8:30 AM ·PRNewswire

FibroBiologics Regains Compliance with Nasdaq Trading Rules

HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on

Aug 26, 2026, 8:30 AM ·PRNewswire

FibroBiologics Appoints Leigh Steinberg to Board of Directors

Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins BoardHOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a

Aug 24, 2026, 8:30 AM ·PRNewswire

FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease

Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat degenerative disc diseaseHOUSTON, Aug. 20, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG)

Aug 20, 2026, 8:30 AM ·PRNewswire

FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints

Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroidsHOUSTON, Aug. 18, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a

Aug 18, 2026, 8:30 AM ·PRNewswire

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

Patent has potential for applications beyond diabetes, including other cell and tissue transplantation proceduresHOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a

Aug 11, 2026, 8:30 AM ·PRNewswire

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting the Company's orthopedics and degenerative disc pathwaysHOUSTON, Aug. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc.

Aug 5, 2026, 8:30 AM ·PRNewswire

FibroBiologics, Inc. Common Stock FBLG · News